Sep 18, 2025 06:39AM Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)

Sep 16, 2025 08:01AM FDA grants Fast Track status to Corbus' CRB-701 for head and neck cancer

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Aug 5, 2025 09:16AM Corbus Pharma (CRBP) Misses Q2 EPS by 144c

Jun 30, 2025 08:19AM Corbus Pharma (CRBP) Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Jun 2, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)

May 21, 2025 06:42AM Corbus Pharmaceuticals (CRBP) PT Lowered to $32 at Mizuho

May 7, 2025 07:17AM Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at H.C. Wainwright

May 6, 2025 04:27PM Corbus Pharma (CRBP) Misses Q1 EPS by 139c

Mar 28, 2025 08:01AM Corbus Pharma (CRBP) Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Mar 12, 2025 06:40AM Corbus Pharmaceuticals (CRBP) PT Lowered to $50 at H.C. Wainwright

Mar 11, 2025 04:26PM Corbus Pharma (CRBP) Misses Q4 EPS by 78c

Feb 28, 2025 02:14AM William Blair Starts Corbus Pharmaceuticals (CRBP) at Outperform

Feb 18, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)

Feb 14, 2025 07:31AM Corbus Pharma (CRBP): CRB-701 A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO

Feb 11, 2025 07:30AM Corbus Pharma (CRBP) to Present Clinical Data for CRB-701

Feb 10, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)

Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'

Dec 17, 2024 07:04AM Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)

Dec 9, 2024 07:04AM Corbus Pharma (CRBP) Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Dec 3, 2024 07:00AM Corbus Pharma (CRBP): FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Dec 2, 2024 04:10AM Piper Sandler Starts Corbus Pharmaceuticals (CRBP) at Overweight

Nov 7, 2024 12:48PM Oppenheimer Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)

Nov 4, 2024 07:02AM Corbus Pharma (CRBP) Presents New CRB-913 Pre-Clinical Data

Oct 21, 2024 06:17AM Oppenheimer Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)

Sep 23, 2024 07:05AM Mizuho Reiterates Corbus Pharmaceuticals (CRBP) at Outperform, 'see a buying opportunity'

Sep 23, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)

Sep 20, 2024 01:04PM Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at B.Riley

Sep 20, 2024 09:32AM Oppenheimer Reiterates Corbus (CRBP) at Outperform, 'could weigh positively for CRBP with CRB-913's substantially lower CNS penetration'

Sep 20, 2024 09:00AM Corbus Pharma (CRBP) Quickly Falls 52%

Sep 20, 2024 09:00AM Corbus Pharma (CRBP) sink over 55% on Novo Nordisk (NVO) data

Sep 13, 2024 06:52AM Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP)

Aug 27, 2024 05:05AM Mizuho Starts Corbus Pharmaceuticals (CRBP) at Outperform

Aug 7, 2024 07:45AM Corbus Pharmaceuticals (CRBP) PT Raised to $88 at Oppenheimer

Aug 6, 2024 09:12AM Corbus Pharma (CRBP) Misses Q2 EPS by 90c

Jun 26, 2024 02:23AM B.Riley Starts Corbus Pharmaceuticals (CRBP) at Buy

Jun 11, 2024 06:12AM Corbus Pharmaceuticals (CRBP) PT Raised to $82 at RBC Capital